La vendita allo scoperto per PermRock Royalty Trust dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di PermRock Royalty Trust. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

PermRock Royalty Trust (NYSE:PRT) Azioni, Report sulle vendite allo scoperto

PermRock Royalty Trust

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

UBS analyst Michael Goldsmith maintains Alpine Income Property Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Neutral and lowers the price target from $16 to $15.

News

Price Target

Analyst Ratings

PINE

UBS Maintains Neutral on Alpine Income Property Tr, Lowers Price Target to $15

<a href="https://x.com/markjcarney/status/1945508348067262837?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/markjcarney/status/1945508348067262837?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

Macro Notification

Politics

General

Canada Prime Minister Carney Says We Continue To Work For A U.S. trade Deal That Works For Canadian Workers, But That Deal Is Not Yet On The Table

WIIM

SCNX

Scienture Holdings shares are trading higher after the company announced it regained Nasdaq compliance.

UBS analyst Michael Goldsmith maintains NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Neutral and lowers the price target from $43 to $42.

UBS Maintains Neutral on NNN REIT, Lowers Price Target to $42

SLXN

Silexion Therapeutics shares are trading lower after the company announced a 1-for-15 reverse stock split.

<a href="https://www.youtube.com/watch?v=VcL0O85hNiA " title="https://www.youtube.com/watch?v=VcL0O85hNiA ">https://www.youtube.com/watch?v=VcL0O85hNiA&nbsp;</a>
&nbsp;

Macro Economic Events

Economics

Federal Reserve

Trump Makes Comments On Fed Chair Powell; Says He's Too Late; He Is Doing Terrible Job; Asked About Firing Powell, Says We Are Not Planning On Doing Anything; His Board Is Not Doing Its Job; We'll Get To Pick A New Chair In About 8 Months, We'll Pick Someone Who Is Good; Kevin Hassett Is Someone We'd Consider For Fed Job;  We Have A Lot Of People Who Want That Job

CGTX

Cognition Therapeutics shares are trading higher after the company announced it will present results from its Phase 2 SHIMMER study at AAIC.

iShares MSCI Israel Capped Investable Market Index Fund

Reuters Cites US Secretary Of State Rubio Saying Looks Like A Misunderstanding Between Syria And Israel; In The Next Few Hours We Hope To See Some Progress To End What We'Ve Seen

UBS analyst Michael Goldsmith maintains Getty Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTY#NYSE">GTY</a>) with a Neutral and lowers the price target from $29 to $28.

UBS Maintains Neutral on Getty Realty, Lowers Price Target to $28

CTXR

Citius Pharmaceuticals shares are trading lower after the company's subsidiary announced the pricing of a $9 million public offering.

UBS analyst Michael Goldsmith maintains Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Buy and lowers the price target from $37 to $36.

EPRT

UBS Maintains Buy on Essential Properties, Lowers Price Target to $36

The Division of Hepatology and Nutrition of the U.S. <a href="https://www.benzinga.com/topic/fda-0">Food and Drug Administration</a> lifted the partial clinical hold on Kezar Life Sciences Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) completed PORTOLA Phase 2a trial evaluating zetomipzomib in autoimmune hepatitis (AIH).
AIH is a chronic liver disease in which the body&#8217;s immune system mistakenly attacks liver cells, leading to inflammation and damage.
Also Read: <a href="https://www.benzinga.com/25/03/44474984/kezar-life-sciences-touts-positive-data-from-mid-stage-study-for-chronic-liver-disease-drug-candidate" target="_blank" rel="noreferrer noopener">Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate</a>
&#8220;We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program,&#8221; said Chris Kirk, CEO and co-founder of Kezar, in a <a href="https://www.benzinga.com/pressreleases/25/07/b46431073/kezar-life-sciences-announces-fda-has-lifted-partial-clinical-hold-on-portola-phase-2a-trial-evalu" target="_blank" rel="noreferrer noopener">statement on Tuesday</a>.
Although Kezar has suspended the development of zetomipzomib in lupus nephritis to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review its safety profile.
The IDMC has provided Kezar with recommendations for conducting future clinical trials in lupus nephritis.
Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in lupus nephritis.
In October 2024, the FDA placed a clinical hold on the zetomipzomib Investigational New Drug (IND) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41206113/fda-put-brakes-on-penny-stock-kezar-life-sciences-mid-stage-study-for-lead-development-candidate-" rel="noreferrer noopener">application for lupus nephritis</a>.
The action followed Kezar's communication to the FDA that Kezar was voluntarily suspending enrollment and dosing in its Phase 2b PALIZADE trial of zetomipzomib in lupus nephritis patients at the recommendation of the trial's independent committee.
The recommendation followed their review of emerging safety data, including an assessment of four Grade 5 (fatal or death) serious adverse events (SAEs) that occurred during the trial in patients enrolled in the Philippines and Argentina.
KZR Price Action: Kezar Life Sciences shares were down 9.09% at $4.20 at the time of publication Wednesday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46437458/alibaba-intensifies-instant-delivery-fight-with-new-campaign" target="_blank" rel="noreferrer noopener">Alibaba Intensifies Instant Delivery Fight With New Campaign</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study

Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) stock gained momentum on Wednesday after Jefferies analyst Brent Thill raised <a target="_blank" href="https://www.benzinga.com/quote/U/analyst-ratings" rel="noreferrer noopener">the price target</a> from $29 to $35 while maintaining a Buy rating.
Over the past three months, seven analysts have issued ratings on Unity, ranging from bullish to somewhat bearish, with four maintaining a positive stance. The 12-month average price target now stands at $26.57, a 2.78% drop from the previous average, reflecting slightly tempered expectations. Forecasts vary significantly, with a high of $35 and a low of $15, according to <a href="https://www.benzinga.com/insights/analyst-ratings/25/07/46441096/beyond-the-numbers-7-analysts-discuss-unity-software-stock">Benzinga Insights</a>.
Notably, Bank of America&#8217;s Omar Dessouky <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46118143/unity-software-stock-is-sliding-today-whats-going-on" rel="noreferrer noopener">reinstated</a> coverage on Unity with an &#8220;Underperform&#8221; rating and a $15 target, contrasting sharply with Jefferies&#8217; bullish outlook.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46326934/unity-shares-are-on-a-three-month-climb-whats-going-on" target="_blank" rel="noreferrer noopener">Unity Shares Are On a Three-Month Climb: What&#8217;s Going On?</a>
Overall, analysts maintain a mixed but cautiously optimistic view on Unity, with most leaning bullish. Despite a slight decline in the average target, many still see upside potential, although views diverge due to uncertainty surrounding the company&#8217;s execution and future growth.
Unity, best known for its video game development platform, is gaining recognition as an emerging player in artificial intelligence. The company recently launched AI-powered tools to enhance developer productivity by automating complex and repetitive tasks. According to Unity&#8217;s <a href="https://www.benzinga.com/markets/options/25/06/45960494/u-unity-stock-hidden-ai-play-statistical-edge" target="_blank" rel="noreferrer noopener">research</a>, 96% of developers are already integrating AI into their workflows, positioning the company as a key contender in the AI-driven software landscape beyond gaming.
The stock has a 52-week high of $30.88 and a 52-week low of $13.90, representing a peak-to-trough decline of approximately 55%.
Price Action: At the last check on Wednesday, U shares were trading higher by 12.02% at $33.26.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46442422/cisco-is-quietly-beating-the-ai-hype-should-investors-pay-closer-attention" target="_blank" rel="noreferrer noopener">Cisco Is Quietly Beating The AI Hype—Should Investors Pay Closer Attention?</a></li>
</ul>
Image: Shutterstock

Unity Stock Jumps After Jefferies Upgrade—Here's What Changed

UBS analyst Michael Goldsmith maintains Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Neutral and lowers the price target from $17 to $16.

UBS Maintains Neutral on Broadstone Net Lease, Lowers Price Target to $16

UBS analyst Michael Goldsmith maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Buy and lowers the price target from $84 to $80.

UBS Maintains Buy on Agree Realty, Lowers Price Target to $80

United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) stock is in the green, rallying on strong chart signals ahead of its <a href="https://www.benzinga.com/quote/UAL/earnings">second quarter earnings</a> report after market close Wednesday.
<h2 class="wp-block-heading">Bullish Technicals Set The Stage For A Breakout</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0716"><img loading="lazy" decoding="async" width="627" height="485" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16111353/Screenshot-2025-07-16-at-8.43.42-PM.png" alt="" class="wp-image-988105" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16111353/Screenshot-2025-07-16-at-8.43.42-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16111353/Screenshot-2025-07-16-at-8.43.42-PM-300x232.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0716">Chart created using Benzinga Pro</a>
Shares are trading around $87.41, comfortably above their eight-, 20-, 50-, and 200-day simple moving averages, a classic bullish indicator that suggests the trend is favorable, despite selling pressure indicating caution ahead.
The Relative Strength Index (RSI) is at 59.90, indicating that the stock has momentum without being overbought. At the same time, the Moving Average Convergence Divergence (MACD) stands at 2.65, confirming strengthening momentum and reinforcing bullish sentiment.
<h2 class="wp-block-heading">Earnings Expectations Soar, But Headwinds Remain</h2>
All eyes are now on United's after-market release, with Wall Street forecasting earnings per share of approximately $3.77 on revenues of nearly $15.35 billion, according to Benzinga Pro data. The travel industry just got a boost after Delta Airlines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) reported a strong quarter &#8211; its positive outlook and easing fuel costs triggered a sector-wide rally, lifting the stock by more than 14%.
Read Also: <a href="https://www.benzinga.com/markets/earnings/25/07/46357934/delta-air-lines-weathers-the-storm-ceo-expects-demand-to-accelerate-to-wrap-2025">Delta Air Lines Weathers The Storm: CEO Expects &#8216;Demand To Accelerate&#8217; To Wrap 2025</a>
If United can echo Delta's performance with solid guidance and cost control, the market rally could gain altitude. However, dark clouds such as labor expenses, aircraft delivery delays, or weaker-than-expected booking demand could quickly ground the stock.
Longer-term, UAL remains down ~8% year-to-date, but still up 86% over the past year—a ride suggesting investors believe in the recovery story, even if the upcoming earnings report marks a turning point.
Whether the post-earnings reaction has lift-off or turbulence will depend on United's ability to match or exceed expectations and whether it can maintain control of costs and outlook.
With bullish technicals in place, the second quarter reveal could be the spark that sends United Airlines to a new cruising altitude, or expose cracks beneath the runway.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46409215/united-airlines-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">United Airlines Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo: Shutterstock

Previews

Trading Ideas

United Airlines Earnings Takeoff: Can Q2 Fuel A Market Rebound?

Rumors

IPOs

AUGO

Aura Minerals IPO Indicating $24.50/Share On 270K Shares; IPO Priced At $24.25/Share On ~8.1M Shares

UBS analyst Chris Kuntarich maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and raises the price target from $80 to $105.

UBS Maintains Buy on Trade Desk, Raises Price Target to $105

James Wynn, <a href="https://www.benzinga.com/markets/25/06/45829284/this-bitcoin-trader-went-from-a-1-billion-long-position-to-begging-for-donations">the pseudonymous crypto trader</a> known for his aggressive leveraged bets, has resumed high-risk trading just weeks after self-reporting losses in the hundreds of millions.
Known for his audacious trading style on the Hyperliquid (CRYPTO: HYPE) platform, Wynn's journey from meteoric gains to catastrophic losses, followed by a dramatic exit from social media and a bold return, offers a human lens into the allure and peril of crypto trading.
Wynn first burst onto the scene in March 2025, when he turned a $3 million position into $100 million through a series of high-leverage trades, primarily on the meme coin Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>).
His most notable feat was transforming a $7,000 investment in PEPE into over $25 million, earning him a cult following among crypto enthusiasts. 
"I started trading perps in March, had never traded perps before, in fact, never really traded properly before," Wynn <a href="https://www.tradingview.com/news/cryptonews:39f602933094b:0-crypto-trader-james-wynn-confesses-he-lost-control-after-losing-100m-in-a-month/">shared</a> on X, admitting his inexperience but reveling in his early success.
His transparency and bold moves drew thousands of followers, who watched his every trade with a mix of awe and apprehension.
However, Wynn's fortunes took a sharp turn in May 2025. &#8216;
He placed a $1.25 billion long position on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) with 40x leverage, betting on a price surge above $108,243. 
When Bitcoin briefly dipped below $105,000, his position was liquidated, wiping out 949 BTC, equivalent to nearly $100 million. 
Just days later, on June 3, Wynn doubled down with another $100 million Bitcoin bet, only to lose $25 million when it was liquidated on June 5. 
"With all this new attention, the trading spiraled out of control. I was basically gambling," Wynn confessed on X, reflecting on how the pressure of his growing audience warped his judgment.
The losses didn't stop there. 
On July 11, 2025, Wynn's 40x leveraged short position on Bitcoin, worth $1.5 million, was liquidated after Bitcoin rallied past $116,000, contributing to a broader wave of $543 million in short-position liquidations that day.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46441190/600m-in-1-day-why-are-bitcoin-ethereum-etf-suddenly-so-bullish">$600M In 1 Day: Why Are Bitcoin, Ethereum ETF Suddenly So Bullish?</a>
Observers on X called his bet a "massive risk," with some suggesting an "Inverse James Wynn" strategy, betting against his moves. 
Devastated, Wynn changed his X profile to "bankrupt" and deactivated his account on July 12, leaving behind a void in the crypto community."
He lost $100m gambling on high leverage with bitcoin barely moving," posted Scott Melker on May 30, calling Wynn's story a "cautionary tale."
Wynn's disappearance from X sparked debate about the sustainability of high-leverage trading. 
His losses, estimated in the hundreds of millions, underscored the risks of betting big in a volatile market. 
"Wynn's dramatic downfall serves as a warning against aggressive speculation," noted a report on ainvest.com, highlighting the need for disciplined risk management. 
Yet, behind the numbers was a human story of ambition and overconfidence, as Wynn himself admitted to "not taking the numbers on the screen seriously."
Remarkably, Wynn's story didn't end with his exit. 
On July 15, 2025, he resurfaced, reactivating his X account and returning to Hyperliquid with a $468,000 deposit. 
He opened a 40x leveraged Bitcoin long position worth $19.5 million at $117,000 and a 10x leveraged PEPE position valued at $102,000. 
According to blockchain analytics platform Lookonchain, Wynn funded these trades partly with a $6,792.53 USDC referral bonus. 
By July 16, his Bitcoin position had gained $161,200, though it faced a liquidation risk if Bitcoin fell below $115,520. 
His PEPE position also showed modest profits of over $6,000. 
"Never financial advice of course. But the MM's are out of gun powder," Wynn posted on X, suggesting market makers could no longer manipulate prices against him.
Wynn's return has reignited fascination and skepticism. 
While some admire his resilience, others, like trader Qwatio, who opened a $2.3 million short position against Bitcoin, see his moves as reckless. "Don't be a James Wynn," warned Scott Melker, emphasizing the dangers of high-leverage trading. 
Yet Wynn's persistence reflects a deeper human drive—a refusal to be defined by failure, even in the face of staggering losses.
As Bitcoin hovers around $117,432 and the crypto market remains a battleground of bulls and bears, Wynn's saga continues to captivate. 
His story is not just about numbers but about the emotional toll of chasing wealth in a high-stakes arena. 
Whether he's a cautionary tale or a symbol of unrelenting ambition, James Wynn's journey reminds us of the human cost, and allure of playing the crypto game.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/07/46433066/bitcoin-dips-below-117-000-what-on-chain-data-reveals-about-the-next-big-price-shift">Bitcoin Dips Below $117,000: What On-Chain Data Reveals About The Next Big Price Shift</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$PEPE

Did He Learn Nothing? Trader Who Lost $100M Returns With High-Leverage Bets On Bitcoin

UBS analyst Doug Harter maintains Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) with a Buy and raises the price target from $17 to $17.5.

Comments

PermRock Royalty Trust

Vendite allo scoperto

PermRock Royalty Trust (NYSE:PRT) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO